- Fresenius Medical Care’s basic earnings per share, excluding special items, increased to EU0.91 from EU0.72 year-on-year, surpassing the estimate of EU0.81.
- Total revenue stood at EU4.79 billion, a slight increase of 0.5% compared to the previous year and exceeding the estimate of EU4.74 billion.
- Operating income was EU425 million, matching the previous year’s figure.
- Operating income, excluding special items, rose by 9.2% year-on-year to EU476 million, although it fell short of the estimated EU485.9 million.
- Net income grew significantly by 20% year-on-year to EU225 million.
- Net income excluding special items increased by 26% year-on-year to EU268 million.
- Basic earnings per share increased to EU0.77 from EU0.64 year-on-year.
- The company confirms its positive outlook for fiscal year 2025.
- Fresenius Medical Care expects revenue growth to remain positive within a low-single digit percent range compared to the previous year.
- The company anticipates an increase in operating income, excluding special items, within a high-teens to high-twenties percent range compared to the prior year.
- Fresenius Medical Care plans to begin the first tranche of its announced share buyback program in August.
A look at Fresenius Medical Care & Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking ahead, Fresenius Medical Care, a company providing kidney dialysis services and related products worldwide, demonstrates strong fundamentals according to Smartkarma Smart Scores. With a solid score across key factors such as Value and Dividend, indicating good value and dividend payouts, Fresenius is positioned well for long-term growth. The company’s moderate scores in Growth, Resilience, and Momentum suggest a stable outlook, with room for potential expansion and resilience in the face of challenges.
Overall, Fresenius Medical Care’s Smart Scores point towards a positive outlook for the company in the long term, reflecting its strong foundation in the healthcare industry. As a leader in kidney dialysis services and a wide range of related treatments and services, Fresenius’ consistent performance in key areas bodes well for its future growth and sustainability in the global market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
